BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enfortumab Vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Enfortumab Vedotin\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04963153-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Enfortumab Vedotin: Phase 1 readout est. (NCT04963153)
DESCRIPTION:Enfortumab Vedotin\, phase 1\, Bladder Cancer.\nStudy: Testing 
 Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cance
 r After Treatment With Chemotherapy and Immunotherapy\nEstimated primary c
 ompletion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04963153
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05756569-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05756569)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Met
 astatic Bladder Cancer of Variant Histology\nEstimated primary completion:
  16 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/en
 fortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05756569
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06862219-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Enfortumab Vedotin: Phase 4 readout est. (NCT06862219)
DESCRIPTION:Enfortumab Vedotin\, phase 4.\nStudy: A Safety Study of Enfortu
 mab Vedotin in Indian Adults With Urothelial Cancer\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06862219
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904573-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06904573)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Probiotics in Advanced Ur
 othelial Carcinoma\nEstimated primary completion: 1 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06904573
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05775471-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05775471)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Pembrolizumab and Enfortu
 mab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterecto
 my for High-Risk Upper Tract Urothelial Cancer\nEstimated primary completi
 on: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nfortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05775471
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04724018-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT04724018)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Sacitu
 zumab Govitecan Plus EV in Metastatic UC\nEstimated primary completion: 1 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfort
 umab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04724018
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891560-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06891560)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: A Study of Enfortumab Ved
 otin in People With Adenoid Cystic Carcinoma\nEstimated primary completion
 : March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfortu
 mab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06891560
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647289-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07647289)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: EV + Tor
 ipalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC\n
 Estimated primary completion: April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07647289
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305767-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06305767)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: A Clin
 ical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in Pe
 ople With Bladder Cancer (V940-005/INTerpath-005)\nEstimated primary compl
 etion: 23 April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /enfortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06305767
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845814-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT05845814)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2.\nStudy: A Study of Efficacy and
  Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational 
 Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KE
 YMAKER-U04)\nEstimated primary completion: 31 May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05845814
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484022-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enfortumab Vedotin: Phase 1 readout est. (NCT07484022)
DESCRIPTION:Enfortumab Vedotin\, phase 1.\nStudy: Study of GB-4362 With Enf
 ortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07484022
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05614739-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enfortumab Vedotin: Phase 1 readout est. (NCT05614739)
DESCRIPTION:Enfortumab Vedotin\, phase 1.\nStudy: FORAGER-1: A Study of Vep
 ugratinib (LY3866288\; LOXO-435) in Participants With Cancer With a Change
  in a Gene Called FGFR3\nEstimated primary completion: June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05614739
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239624-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05239624)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin and Pembrolizumab in People With Bladder Cancer\nEstimated prim
 ary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05239624
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906822-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06906822)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: PLUG-IN: Pembrolizumab Co
 mbined With Enfortumab Vedotin for Advanced Melanoma Patients\nEstimated p
 rimary completion: June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06906822
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332351-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07332351)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Neoadjuv
 ant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pemb
 rolizumab for the Treatment of Muscle Invasive Bladder Cancer\, TRIFECTA T
 rial\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07332351
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868265-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270602
DTEND;VALUE=DATE:20270603
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05868265)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: A Study of Enfortumab Ved
 otin in People With Urothelial Carcinoma of the Upper Urinary Tract\nEstim
 ated primary completion: 2 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05868265
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Protein-Matched ADC or PD
 C Umbrella Trial in Advanced Pancreatic and Breast Cancer\nEstimated prima
 ry completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07825753
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629700-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Enfortumab Vedotin: Phase na readout est. (NCT07629700)
DESCRIPTION:Enfortumab Vedotin\, phase na.\nStudy: Study of Peripheral Neur
 opathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab
  Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)\nEstimated
  primary completion: 1 September 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07629700
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06434350-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06434350)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Enfort
 umab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDA
 TE)\nEstimated primary completion: 24 September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06434350
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06302569-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06302569)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Pembrolizumab Plus Enfort
 umab Vedotin in Collecting Duct and Renal Medullary Carcinoma\nEstimated p
 rimary completion: October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06302569
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06041503-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06041503)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Enfortumab Vedotin With o
 r Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)\nEstimated
  primary completion: 1 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06041503
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06809140-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06809140)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment
  of Muscle-invasive Bladder Cancer\nEstimated primary completion: November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06809140
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04878029-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271113
DTEND;VALUE=DATE:20271114
SUMMARY:Enfortumab Vedotin: Phase 1 readout est. (NCT04878029)
DESCRIPTION:Enfortumab Vedotin\, phase 1.\nStudy: Cabozantinib in Combinati
 on With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial C
 ancer\nEstimated primary completion: 13 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04878029
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139977-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07139977)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Study of EV for Recurrent
  Endometrial Carcinoma\nEstimated primary completion: 30 November 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07139977
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07475806-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07475806)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: A Study 
 to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People Wi
 th Muscle-invasive Bladder Cancer Keep Their Bladder\nEstimated primary co
 mpletion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07475806
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421700-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07421700)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2.\nStudy: Symbiotic-GU-06: A Stud
 y to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedot
 in in Urothelial Cancer\nEstimated primary completion: 28 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0742170
 0
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217496-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Enfortumab Vedotin: Phase 1 readout est. (NCT07217496)
DESCRIPTION:Enfortumab Vedotin\, phase 1\, Bladder Cancer.\nStudy: N-803 in
  Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Ur
 othelial Cancer\nEstimated primary completion: January 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07217496
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470282-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06470282)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Enfort
 umab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasi
 ve Bladder Cancer\nEstimated primary completion: 31 January 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06470282
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183319-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07183319)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Circulating Tumor DNA Res
 ponse In Urothelial Cancer\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07183319
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356155-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06356155)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Study of Neoadjuvant Enfo
 rtumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer\nEstimat
 ed primary completion: March 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06356155
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483334-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06483334)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2.\nStudy: A Study of Efficacy and
  Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) 
 With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-0
 4C/KEYMAKER-U04)\nEstimated primary completion: 31 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06483334
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311214-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06311214)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Personalized Antibody-Dru
 g Conjugate Therapy Based on RNA and Protein Testing for the Treatment of 
 Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment
  Trial)\nEstimated primary completion: 31 March 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06311214
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05656235-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05656235)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Renal Re
 tention in High Grade Upper Tract Urothelial Cancer\nEstimated primary com
 pletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nfortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05656235
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374549-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07374549)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: SYS6002 vs PADCEV in Pati
 ents With Advanced Urothelial Carcinoma\nEstimated primary completion: 1 J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-
 vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07374549
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06104618-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06104618)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Enfortumab Vedotin for th
 e Treatment of Patients With Metastatic or Unresectable Squamous Cell Carc
 inoma of the Penis\nEstimated primary completion: 1 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06104618
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923190-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT05923190)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Enfortumab Vedotin Schedu
 le De-escalation in Metastatic Urothelial Carcinoma\nEstimated primary com
 pletion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /enfortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05923190
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764095-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Enfortumab Vedotin: Phase 4 readout est. (NCT06764095)
DESCRIPTION:Enfortumab Vedotin\, phase 4\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Local
 ly Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer\, CAST
 -AI Trial\nEstimated primary completion: 1 July 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06764095
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Precision Treatment of Re
 current/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEs
 timated primary completion: 10 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087860-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07087860)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Therapeu
 tic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatmen
 t of Bladder Cancers\nEstimated primary completion: 7 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07087860
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157956-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280812
DTEND;VALUE=DATE:20280813
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07157956)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2.\nStudy: CVL006 Combination Ther
 apy in Advanced Solid Tumors\nEstimated primary completion: 12 August 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0715
 7956
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221942-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07221942)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Pembrolizumab Maintenance
  After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic U
 rothelial Carcinoma\nEstimated primary completion: 1 September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07221942
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06394570-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT06394570)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Enfort
 umab Vedotin and Stereotactic Radiation for Localized Bladder Cancer\nEsti
 mated primary completion: 30 September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06394570
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347314-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07347314)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Enfortumab Vedotin in Pat
 ients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to
  Platinum-based Combination Therapy\nEstimated primary completion: 30 Sept
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfortuma
 b-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07347314
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643519-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07643519)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Neoadjuv
 ant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cance
 r and Upper Tract Urothelial Carcinoma\nEstimated primary completion: Febr
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab
 -vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07643519
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110038-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07110038)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: DEPECA-1 - A Phase II Stu
 dy to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus 
 Avelumab for Advanced and Metastatic Penile Carcinoma\nEstimated primary c
 ompletion: May 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 enfortumab-vedotin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07110038
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287995-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07287995)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2.\nStudy: A Study of ASP2998 Give
 n by Itself and Given With Standard Therapies in People With Solid Tumors\
 nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07287995
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667335-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290716
DTEND;VALUE=DATE:20290717
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07667335)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: Enfort
 umab Vedotin\, Pembrolizumab and Quemliclustat for the Treatment of Unrese
 ctable Locally Advanced and Metastatic Urothelial Cancer\nEstimated primar
 y completion: 16 July 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07667335
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06553885-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT06553885)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Ph II Study of Enfortumab
  Vedotin in Patients With Advanced or Metastatic CRC or HCC\nEstimated pri
 mary completion: September 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06553885
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTu
 mor04 (TP04)]\nEstimated primary completion: 30 September 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908979-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07908979)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Risk-Ena
 bled Therapy After Initiating EV/Pembro for Bladder Cancer\nEstimated prim
 ary completion: 1 October 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07908979
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566156-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Enfortumab Vedotin: Phase 3 readout est. (NCT07566156)
DESCRIPTION:Enfortumab Vedotin\, phase 3\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiother
 apy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)\nEstimat
 ed primary completion: 31 March 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07566156
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03547973-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT03547973)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Study of Sacituzumab Govi
 tecan in Participants With Urothelial Cancer That Cannot Be Removed or Has
  Spread\nEstimated primary completion: April 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03547973
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863765-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300505
DTEND;VALUE=DATE:20300506
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07863765)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: Enfortumab Vedotin for th
 e Treatment of Unresectable or Metastatic Radioiodine Refractory Different
 iated Thyroid Cancer\, Anaplastic Thyroid Cancer\, Medullary Thyroid Cance
 r\, or NUT Carcinoma\nEstimated primary completion: 5 May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07863765
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815665-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Enfortumab Vedotin: Phase 2/3 readout est. (NCT07815665)
DESCRIPTION:Enfortumab Vedotin\, phase 2/3.\nStudy: A Study of Ivonescimab 
 in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination Wit
 h Enfortumab Vedotin in Metastatic Urothelial Carcinoma\nEstimated primary
  completion: 31 October 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07815665
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07346053-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Enfortumab Vedotin: Phase 3 readout est. (NCT07346053)
DESCRIPTION:Enfortumab Vedotin\, phase 3\, Bladder Cancer.\nStudy: The Impa
 ct of Time-of-day Administration of EV/P on Objective Response Rate in Adu
 lts With Advanced Bladder Cancer\nEstimated primary completion: December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedot
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7346053
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663747-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07663747)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC\nEstimat
 ed primary completion: 1 April 2031. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07663747
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232602-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310708
DTEND;VALUE=DATE:20310709
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07232602)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Bladder Cancer.\nStudy: KEYMAK
 ER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortu
 mab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04
 D/KEYMAKER-U04)\nEstimated primary completion: 8 July 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07232602
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822373-2121@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20341130
DTEND;VALUE=DATE:20341201
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07822373)
DESCRIPTION:Enfortumab Vedotin\, phase 2.\nStudy: A Phase 2 Study Evaluatin
 g Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patie
 nts With Muscle-Invasive Urothelial Cancer\nEstimated primary completion: 
 November 2034. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enfort
 umab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07822373
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
